4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
4D Molecular Therapeutics, Inc. (FDMT)
Company Research
Source: GlobeNewswire
Enrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of initial projections 4FRONT-1 overenrolled and expected to exceed 500 patients randomized, reflecting strong interest from investigators and patients Topline data from 4FRONT-1 expected in H1 20274FRONT-2 global site activation momentum continues, with enrollment completion on track for H2 2026 and topline data expected in H2 2027 EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced enrollment completion for 4FRONT-1, the first Phase 3 clinical trial evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD). “The 4D-150 4FRONT-1 Phase 3 trial enrolled
Show less
Read more
Impact Snapshot
Event Time:
FDMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FDMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FDMT alerts
High impacting 4D Molecular Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FDMT
News
- Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT) [Yahoo! Finance]Yahoo! Finance
- 4D Molecular Therapeutics (NASDAQ:FDMT) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $33.00 price target on the stock.MarketBeat
- 4DMT Announces New Employment Inducement GrantsGlobeNewswire
- 4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- 4DMT Provides Company Update and Anticipated Development Milestones for 2026GlobeNewswire
FDMT
Earnings
- 11/10/25 - Beat
FDMT
Sec Filings
- 2/9/26 - Form SCHEDULE
- 1/26/26 - Form 8-K
- 1/7/26 - Form 4
- FDMT's page on the SEC website